Nathan E K Procter1, Jocasta Ball2, Doan T M Ngo1, Yuliy Y Chirkov1, Jeffrey S Isenberg3, Elaine M Hylek4, Simon Stewart2,5, John D Horowitz6. 1. Basil Hetzel Institute, Department of Cardiology, The Queen Elizabeth Hospital, University of Adelaide, Cardiology Unit, 28 Woodville Rd, Woodville South, 5011, SA, Australia. 2. National Health and Medical Research Council (NHMRC) Centre of Research Excellence to Reduce Inequality in Heart Disease, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia. 3. Heart, Lung, Blood and Vascular Medicine Institute, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 4. School of Medicine, Boston University, Boston, MA, USA. 5. Baker IDI Heart and Diabetes Institute, Melbourne, Australia. 6. Basil Hetzel Institute, Department of Cardiology, The Queen Elizabeth Hospital, University of Adelaide, Cardiology Unit, 28 Woodville Rd, Woodville South, 5011, SA, Australia. john.horowitz@adelaide.edu.au.
Abstract
OBJECTIVE: Atrial fibrillation (AF) is a condition where platelet hyperaggregability is commonly present. We examined potential physiological bases for platelet hyperaggregability in a cohort of patients with acute and chronic AF. In particular, we sought to identify the impact of inflammation [myeloperoxidase (MPO) and C-reactive protein (CRP)] and impaired nitric oxide (NO) signaling. METHODS: Clinical and biochemical determinants of adenosine diphosphate (ADP)-induced platelet aggregation were sought in patients (n = 106) hospitalized with AF via univariate and multivariate analysis. RESULTS: Hyper-responsiveness of platelets to ADP was directly (r = 0.254, p < 0.01) correlated with plasma concentrations of thrombospondin-1 (TSP-1), a matricellular protein that impairs NO responses and contributes to development of oxidative stress. In turn, plasma TSP-1 concentrations were directly correlated with MPO concentrations (r = 0.221, p < 0.05), while MPO concentrations correlated with those of asymmetric dimethylarginine (ADMA, r = 0.220, p < 0.05), and its structural isomer symmetric dimethylarginine (SDMA, r = 0.192, p = 0.05). Multivariate analysis identified TSP-1 (β = 0.276, p < 0.05) concentrations, as well as female sex (β = 0.199, p < 0.05), as direct correlates of platelet aggregability, and SDMA concentrations (β = - 0.292, p < 0.05) as an inverse correlate. CONCLUSION: We conclude that platelet hyperaggregability, where present in the context of AF, may be engendered by impaired availability of NO, as well as via MPO-related inflammatory activation.
OBJECTIVE:Atrial fibrillation (AF) is a condition where platelet hyperaggregability is commonly present. We examined potential physiological bases for platelet hyperaggregability in a cohort of patients with acute and chronic AF. In particular, we sought to identify the impact of inflammation [myeloperoxidase (MPO) and C-reactive protein (CRP)] and impaired nitric oxide (NO) signaling. METHODS: Clinical and biochemical determinants of adenosine diphosphate (ADP)-induced platelet aggregation were sought in patients (n = 106) hospitalized with AF via univariate and multivariate analysis. RESULTS: Hyper-responsiveness of platelets to ADP was directly (r = 0.254, p < 0.01) correlated with plasma concentrations of thrombospondin-1 (TSP-1), a matricellular protein that impairs NO responses and contributes to development of oxidative stress. In turn, plasma TSP-1 concentrations were directly correlated with MPO concentrations (r = 0.221, p < 0.05), while MPO concentrations correlated with those of asymmetric dimethylarginine (ADMA, r = 0.220, p < 0.05), and its structural isomer symmetric dimethylarginine (SDMA, r = 0.192, p = 0.05). Multivariate analysis identified TSP-1 (β = 0.276, p < 0.05) concentrations, as well as female sex (β = 0.199, p < 0.05), as direct correlates of platelet aggregability, and SDMA concentrations (β = - 0.292, p < 0.05) as an inverse correlate. CONCLUSION: We conclude that platelet hyperaggregability, where present in the context of AF, may be engendered by impaired availability of NO, as well as via MPO-related inflammatory activation.
Authors: Melinda J Carrington; Jocasta Ball; John D Horowitz; Thomas H Marwick; Gnanadevan Mahadevan; Chiew Wong; Walter P Abhayaratna; Brian Haluska; David R Thompson; Paul A Scuffham; Simon Stewart Journal: Int J Cardiol Date: 2011-11-12 Impact factor: 4.164
Authors: Jan T Kielstein; Shelley R Salpeter; Stefanie M Bode-Boeger; John P Cooke; Danilo Fliser Journal: Nephrol Dial Transplant Date: 2006-06-09 Impact factor: 5.992
Authors: B M Psaty; T A Manolio; L H Kuller; R A Kronmal; M Cushman; L P Fried; R White; C D Furberg; P M Rautaharju Journal: Circulation Date: 1997-10-07 Impact factor: 29.690
Authors: David R Soto-Pantoja; Erica V Stein; Natasha M Rogers; Maryam Sharifi-Sanjani; Jeffrey S Isenberg; David D Roberts Journal: Expert Opin Ther Targets Date: 2012-10-27 Impact factor: 6.902